ADGRF2

Across TCGA pan-cancer cohorts, ADGRF2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ADGRF2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ADGRF2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ADGRF2 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

THCA, BRCA, and KICH are the cancer types where ADGRF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADGRF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	+0.227	<.001	6	view →
BRCA	All	All	+0.047	<.001	6	view →
KICH	All	All	−0.471	<.001	5	view →
LUSC	Male	All	+0.333	<.001	4	view →
BLCA	Male	All	+0.283	.011	4	view →
KIRP	All	IV	+0.347	.041	2	view →
COAD	All	All	+0.041	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ADGRF2–THCA

Open the THCA breakdown →